Protalix BioTherapeutics (NYSE:PLX) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Protalix BioTherapeutics (NYSE:PLXGet Rating) in a report issued on Monday. The brokerage set a “buy” rating on the stock.

Protalix BioTherapeutics Price Performance

Protalix BioTherapeutics stock opened at $1.14 on Monday. Protalix BioTherapeutics has a one year low of $0.70 and a one year high of $2.00. The stock has a market capitalization of $56.72 million, a PE ratio of -2.92 and a beta of 1.78. The firm’s fifty day simple moving average is $1.12.

Protalix BioTherapeutics Company Profile

(Get Rating)

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.

Featured Articles

Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.